Loading...
Dalfampridine extended release tablets: 1 year of postmarketing safety experience in the US
BACKGROUND: Dalfampridine extended release tablets (dalfampridine-ER; prolonged-, modified, or sustained-release fampridine in some countries) were approved in the US to improve walking in patients with multiple sclerosis, as demonstrated by improvement in walking speed. Postmarketing safety experie...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2013
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3647381/ https://ncbi.nlm.nih.gov/pubmed/23662056 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/NDT.S41596 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|